Demand for potassium iodide has increased in the wake of tweets from President Donald Trump about his nuclear powers compared with North Korea's Kim Jong-un, according to Troy Jones, who runs a website that sells the drug. "On Jan. 2, I basically got in a month's supply of potassium iodide and I sold out in 48 hours," says Jones, a top distributor of the drug in the United States. His firm, based in Mooresville, NC, sells all three types of radiation poisoning treatments approved by FDA, with no prescription is required. During that 2-day period, Jones says he shipped about 140,000 doses of potassium iodide, compared with typical sales of about 8,400 doses to private individuals in that time. Jones also sells to government agencies, hospitals, and universities, which are not included in that tally. Alan Morris, president of the Williamsburg, VA-based pharmaceutical firm Anbex, which also distributes potassium iodide, says he has also seen an increase in demand. Jones says this is not the first time in recent months that concerns over growing nuclear tensions have boosted sales of potassium iodide. He also noted increases after Trump's election win, the Fukushima Daichii disaster, and North Korea's initial missile launches.